Loading...
01/09 22:26
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary shows strong revenue growth, successful product launches, and a solid biosimilars performance. The company has reaffirmed strong financial guidance and is investing in manufacturing and R&D. Despite some vague responses in the Q&A, the overall sentiment is positive due to continued growth and strategic investments. The reaffirmation of guidance and no major negative surprises suggest a positive stock price movement.
Revenue Revenues grew by 9% year-over-year to $9.2 billion, driven by key growth drivers such as Repatha, EVENITY, TEZSPIRE, innovative oncology, rare disease, and biosimilar portfolios.
Volume Growth Volume increased by 13% year-over-year, with 15 products delivering at least double-digit sales growth, showcasing the strength of the portfolio.
Repatha Sales Repatha delivered $696 million in the second quarter, up 31% year-over-year, driven by improved access and an expanding prescriber base.
EVENITY Sales EVENITY sales increased 32% year-over-year to $518 million, with U.S. sales growing 41% due to increased prescription volume and newly activated prescriber accounts.
Prolia Sales Prolia sales declined 4% year-over-year to $1.1 billion, driven by lower net selling price and the launch of 3 biosimilars in the U.S.
Rare Disease Portfolio Rare disease portfolio grew 19% year-over-year, delivering nearly $1.4 billion in sales, driven by products like TEPEZZA and UPLIZNA.
TEPEZZA Sales TEPEZZA grew 5% year-over-year to $505 million, supported by increased engagement with prescribers and a successful launch in Japan.
UPLIZNA Sales UPLIZNA sales increased 91% year-over-year to $176 million, driven by its position as the #1 prescribed FDA-approved treatment for NMOSD and FDA approval for IgG4-related disease.
TEZSPIRE Sales TEZSPIRE sales increased 46% year-over-year to $342 million, with growth driven by its differentiated profile and increasing adoption in severe asthma.
Innovative Oncology Portfolio Innovative oncology portfolio grew 14% year-over-year to $2.2 billion, driven by products like IMDELLTRA and BLINCYTO, which are redefining standards of care in cancer treatment.
Biosimilar Portfolio Biosimilar portfolio sales grew 40% year-over-year to $661 million, with PAVBLU, a biosimilar to EYLEA, reaching $130 million in the second quarter.
Non-GAAP R&D Expenses Non-GAAP R&D expenses increased 18% year-over-year to $1.7 billion, reflecting continued investment in late-stage pipeline programs like MariTide, olpasiran, and IMDELLTRA.
Free Cash Flow The company generated $1.9 billion in free cash flow in the second quarter, reflecting operational momentum and continued investment in innovation.
Repatha: Delivered $696 million in Q2, up 31% YoY. Improved access and direct-to-consumer campaigns are driving growth.
EVENITY: Sales increased 32% YoY to $518 million. U.S. sales grew 41%, with over 700,000 patients treated in Japan since launch.
TEPEZZA: Grew 5% to $505 million in Q2. Launched in Japan in December, with positive feedback from endocrinologists.
UPLIZNA: Sales increased 91% YoY to $176 million. Approved for IgG4-related disease and preparing for launch in generalized myasthenia gravis.
TEZSPIRE: Sales up 46% YoY to $342 million. Gaining share in severe asthma market with under 25% U.S. biologic penetration.
IMDELLTRA: Generated $134 million in Q2. Positioned as standard of care in second-line small cell lung cancer.
BLINCYTO: Sales grew 45% YoY to $384 million. Positioned as preferred consolidation therapy in NCCN guidelines.
PAVBLU: Biosimilar to EYLEA, reached $130 million in Q2. Positive reception from retina specialists.
Biosimilars: Sales grew 40% YoY to $661 million. Significant contributor to top-line growth.
International Expansion: TEPEZZA launched in Japan in December. EVENITY has treated over 700,000 patients in Japan.
AI Integration: Investments in AI across discovery, development, and commercial execution to enhance productivity.
R&D Investment: Non-GAAP R&D expenses grew 18% YoY, focusing on late-stage pipeline including MariTide and IMDELLTRA.
Obesity Pipeline: MariTide advancing with four Phase III studies underway, targeting obesity and related conditions.
Cardiovascular Innovation: Repatha and olpasiran focus on precision medicine for cardiovascular risk reduction.
Oncology Leadership: IMDELLTRA and BLINCYTO redefining standards of care in cancer treatment.
Net selling prices for medicines: Declining net selling prices across the industry could impact revenue growth and profitability.
Pricing and tariffs: Ongoing discussions with government officials about pricing and tariffs could lead to regulatory or financial challenges.
Prolia sales: Sales declined 4% year-over-year due to lower net selling prices and competition from three biosimilars launched in the U.S.
Biosimilar competition: Increased competition from biosimilars, particularly for products like Prolia, could erode market share and revenue.
Regulatory hurdles: Upcoming regulatory decisions, such as the December 14 PDUFA date for UPLIZNA and October 19 PDUFA date for TEZSPIRE, could impact product approvals and market entry.
R&D investment: Significant R&D investments, including a 20% increase in 2025, could strain financial resources if expected returns are not realized.
Tariffs and pricing actions: Uncertainty around tariffs and pricing actions not yet implemented could affect financial planning and profitability.
Market dynamics for biosimilars: Initial market dynamics for biosimilars are unfolding, and their impact on revenue remains uncertain.
Operational expenses: Non-GAAP operating expenses rose 8%, driven by increased R&D spending, which could pressure margins.
Revenue Expectations: Amgen expects total revenues for 2025 to be in the range of $35.0 billion to $36.0 billion.
Earnings Per Share (EPS): Non-GAAP earnings per share for 2025 are projected to be between $20.20 and $21.30.
Operating Margin: The company anticipates a full-year non-GAAP operating margin as a percentage of product sales to be roughly 45%.
Research and Development (R&D) Expenses: Non-GAAP R&D expenses are expected to grow over 20% in 2025, reflecting investments in late-stage pipeline programs such as MariTide, olpasiran, and IMDELLTRA.
Capital Expenditures: Capital expenditures for 2025 are projected to be $2.3 billion, aimed at expanding network capacity for products and the innovative pipeline, including MariTide.
AI Investments: Amgen is accelerating innovation and productivity through AI investments across the value chain, including discovery, development, commercial execution, and G&A.
Product Launches and Pipeline: The company is advancing late-stage programs, including MariTide for obesity, olpasiran for cardiovascular risk reduction, and IMDELLTRA for small cell lung cancer. Regulatory filings and additional Phase III studies are underway for these products.
Biosimilars Portfolio: The biosimilars portfolio continues to grow, with PAVBLU, a biosimilar to EYLEA, gaining momentum and reaching $130 million in sales in Q2 2025.
Market Trends and Opportunities: Amgen sees substantial growth opportunities in biologics for severe asthma, obesity treatments, and innovative oncology therapies. The company is also focused on expanding its presence in underserved patient populations and leveraging AI for operational efficiency.
Dividend Payments: Amgen returned capital to shareholders through competitive dividend payments of $2.38 per share, representing a 6% increase compared to the second quarter of 2024.
Share Repurchase: Amgen expects share repurchases not to exceed $500 million in 2025.
The earnings call reflects a positive outlook with strong product development, strategic focus on biosimilars, and promising pipeline assets like VESALIUS-CV and MariTide. Despite some unclear management responses, the emphasis on growth drivers, disciplined capital allocation, and innovative strategies in obesity and cardiovascular markets suggest a positive sentiment. The Q&A reveals enthusiasm for future opportunities and robust R&D investments, supporting a positive stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
